InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches the new Plugin for Sublime Text editor to highlight Heta language code. Heta project is InSysBio’s initiative for the development of infrastructure for modeling in pharmacology and systems biology. The project also summarizes best practices and InSysBio’s experience in modeling of dynamical systems: systems biology, PK/PD, QSP as well as implementation of software development techniques in modeling routine.
Now Sublime Text supports Heta language due to the new Plugin developed by InSysBio Software Development team. It provides an opportunity for Heta code markup and highlighting in the popular text editor Sublime Text. The Plugin is available in the official repository: https://packagecontrol.io/packages/Heta
Heta infrastructure embraces three components:
Heta language is a domain-specific modeling language (DSL) for dynamic quantitative models used in QSP and systems biology. Heta code and tabular formats can be translated into variety of formats like Simbiology, Matlab, DBSolve and many others. In general, the main purpose of the package is to establish the linkage between emerging QSP frameworks and fast computational methods.
Recently, Heta compiler Online has been presented to simplify user experience. Now it is possible to try Heta compiler without installation or any other additional steps here: https://heta-online.insysbio.com/
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | July 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
1.
14 Jul 2017 18:49
To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created
Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
1.
25 Jul 2017 13:50
InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc.
Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
2.
25 Jul 2017 17:37
InSysBio will present at the American Conference on Pharmacometrics (ACoP8)!
Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
